Exercise, specifically resistance training and zone 2 cardio, remains the most validated longevity intervention in the published literature. The evidence base is not comparable to any pharmaceutical or supplementation intervention in depth, breadth, or effect size. Muscle strength maintained through resistance training is amongst the most powerful independent predictors of all-cause mortality across age groups. VO2 max, the measure of cardiovascular fitness most directly associated with longevity outcomes, is improved most durably through zone 2 aerobic training, sustained moderate-intensity exercise in the metabolic zone associated with mitochondrial density increase and fat oxidation efficiency. For the executive population, resistance training also preserves lean muscle mass, the primary site of glucose disposal, making it directly relevant to the insulin resistance trajectory that chronic stress accelerates.

The glymphatic system, the brain’s waste-clearance mechanism, most active during slow-wave sleep, clears amyloid-beta and tau proteins during the overnight rest period. The relationship between chronic sleep insufficiency and accelerated neurodegenerative risk is now established with sufficient confidence that sleep has been included as a modifiable risk factor in major dementia prevention frameworks. For executives whose sleep architecture is demonstrably compromised, assessed through wearable data and longitudinal HRV tracking, restoration of deep sleep is arguably the single highest-return biological intervention available.

The insulin resistance trajectory, chronic cortisol elevation driving persistent hyperglycaemia, compensatory hyperinsulinaemia, and progressive peripheral insulin resistance, is directly modifiable through time-restricted eating, carbohydrate quality management, and protein distribution strategies that preserve lean mass and improve metabolic flexibility. These interventions are supported by a substantial and growing evidence base, are accessible without specialist referral, and address the primary metabolic pathway through which occupational stress accelerates biological ageing.

The specific depletions that chronic occupational stress produces, including magnesium, Vitamin D, B-complex vitamins, and omega-3 index, are measurable through targeted bloodwork and correctable through protocol-based supplementation. The clinical evidence for micronutritional sufficiency in these specific categories, within the context of cognitive performance and stress resilience, is solid and consistent with mainstream clinical consensus.

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism and DNA repair. Its levels decline with age and with the chronic metabolic stress that occupational load produces. The hypothesis that supplementation with NAD+ precursors, specifically NMN and NR, which the body converts to NAD+, can restore youthful cellular energetics and improve mitochondrial function is well-grounded in the basic science, and animal model data is compelling. The human clinical trial data is more modest. Several trials have confirmed that oral supplementation does raise circulating NAD+ levels in humans. Whether this translates into improved mitochondrial function, reduced biological ageing rate, or cognitive enhancement has not yet been established with the consistency or effect sizes that would allow confident clinical recommendation. Generally well-tolerated; functional benefit in healthy individuals remains preliminary.

Rapamycin, an mTOR inhibitor originally developed as an immunosuppressant, has attracted significant attention in the longevity research community following its demonstration of lifespan extension in multiple animal models, including some of the most robust data in the field. The proposed mechanism, periodic mTOR inhibition mimicking the cellular stress-response pathways activated by caloric restriction, is scientifically credible. Human longevity application is genuinely at the experimental frontier. It is being used by a number of longevity medicine practitioners in low-dose, intermittent protocols, reasoning that the immunosuppressive effects dominant at therapeutic transplant doses are substantially reduced at the doses being used. The honest characterisation: this is an informed experiment in humans, not a clinically validated protocol. The risk-benefit calculus for a healthy 45-year-old executive is not yet established by evidence.

Senescent cells, cells that have ceased dividing but resist apoptosis and secrete a pro-inflammatory cocktail of cytokines, accumulate with age and are increasingly recognised as drivers of tissue dysfunction and systemic inflammation. Senolytic compounds, with dasatinib and quercetin being the most studied combination, have demonstrated the ability to selectively clear senescent cells in animal models, with improvements in physical function, inflammatory markers, and lifespan. Human trials are underway but limited. The evidence is promising and the biological rationale is sound; clinical application in healthy individuals remains premature by conventional evidence standards.

Before any intervention, established or experimental, the individual’s current biological state should be assessed through comprehensive biomarker testing. The interventions that produce the most return are not the newest or most novel. They are the ones that address confirmed deficiencies and measurable dysfunctions in the specific individual’s biology.

Begin with the interventions carrying the strongest evidence base, exercise, sleep architecture, metabolic health, micronutritional correction, before moving to the evidence-emerging or experimental categories. The established interventions frequently produce enough improvement in target outcomes that experimental interventions become unnecessary or can be evaluated against a stable and well-characterised biological baseline.

The value of any biological optimisation intervention, established or experimental, is proportional to the quality of the measurement framework around it. Pre and post biomarker assessment, longitudinal tracking of the specific outcomes the intervention is targeting, and the discipline to attribute changes to specific inputs rather than the aggregate noise of simultaneous protocol changes.

A practitioner who understands the evidence landscape, can contextualise experimental interventions within an individual’s specific biological profile, and can distinguish between the genuinely promising and the commercially motivated is the primary safeguard against the risk that the longevity market’s commercial momentum outpaces its evidential one.